NeuroPace, the developer of the RNS implantable brain stimulator for the treatment of drug-refractory focal epilepsy, hopes to raise $75m in an initial public offering.
On 24 March, the Silicon Valley company filed an S-1 registration statement with the US Securities and Exchange Commission, announcing plans to offer its stock on the NASDAQ exchange...